The call covered Moderna's $1.9 billion 2025 revenue, $2 billion in cost savings, and net loss of $2.1 billion, ending with $8.1 billion in cash. Highlights included successful launches of COVID-19 vaccines, partnerships for proclen acidemia, and progress in oncology pipeline with David Berman joining as CDO. Challenges discussed were FDA regulatory uncertainty impacting innovation and patient access.

Revenue reached $700 million Q4, $1.9 billion for 2025, with strong international growth projected for 2026. Cost efficiencies and investment in RD highlighted, ending 2025 with $8.1 billion in cash and investments.

The company forecasts 2026 revenue, considering potential drops in COVID-19 vaccination rates, and projects cost of sales at $900 million with improved gross margins. R&D expenses are set at approximately $1 billion, reflecting disciplined investment in late-stage pipelines. Commercial spending is expected to increase in the second half, aligning with product launches and geographic expansion. GAAP operating expenses are estimated at $4.9 billion, excluding stock-based compensation. Capital expenditures are planned between $200 and $300 million, including investments in U.S. fill-finish capacity. The strategy aims to enhance financial performance with strong momentum from 2025, marked by improved commercial execution and exceeding cost reduction targets.

Moderna anticipates revenue growth from 2026 driven by strategic partnerships in the UK, Canada, and Australia, the launch of MNCs bike, and expansion into European, Latin American, and Asian markets. The company expects significant market share gains with its flu and COVID-19 vaccines, alongside preparations for new vaccine launches and global collaborations.

Moderna updates on global vaccine approvals, including mRNA-1010 and mNXBike, advances in oncology with INx therapy, and a robust financial strategy aiming for 10% revenue growth and cost reductions. Key milestones include Phase III enrollments and regulatory submissions, alongside progress in rare diseases and a focus on AI-driven productivity enhancements.

Discussion on the progress of flu vaccine filings in Europe, Canada, and Australia, targeting contributions by 2027. Inquiry into U.S. FDA engagement for flu-COVID combo product. Emphasis on innovation for senior health amid strain mismatches. Financial guidance impacted by regulatory timelines.

The dialogue highlights the company's cautious stance amidst fluid market conditions, emphasizing potential growth through international partnerships, upcoming market expansions, and cost productivity initiatives. Despite uncertainties, particularly regarding flu product resolutions, the speaker expresses optimism about substantial revenue growth opportunities and the company's robust financial position, concluding that predicting specific outcomes remains premature.

The dialogue covers updates on multiple clinical trials for cancers including melanoma, renal cell carcinoma, bladder, gastric, and pancreatic cancers. It emphasizes the event-driven nature of trials, particularly for melanoma and renal cell carcinoma, with no specific guidance due to the unpredictable timing of event accrual. The speaker also mentions the phase 1 data for gastric and adjuvant pancreatic monotherapy, indicating a busy period ahead with numerous anticipated readouts.

The dialogue covers updates on the regulatory status of the flu-Covid combination vaccine in the US, including data from phase 3 studies showing superior efficacy. It also discusses the highest probability of success for Tisagene Maralix in adjuvant melanoma, supported by strong five-year survival data, with potential read-through to other cancer types.

Discussions centered on the European Covid vaccination market, emphasizing the potential of a combination flu-Covid vaccine, market expansion strategies, and the importance of strain-matching in flu vaccines. Highlights included the product's competitive profile, international approval pathways, and the demand for regionally tailored vaccines.

The dialogue explains the factors contributing to a higher cash balance at year-end, including better-than-expected cash costs, loan proceeds, reduced capital expenditures, and strong working capital management. It also outlines potential levers for lowering cash costs in the future, emphasizing the team's performance in managing receivables, inventory, and payables efficiently.

Discussed the interim analysis approach in the Adjutant three-i Melanoma study, focusing on relapse-free survival as a primary endpoint. If early success isn't declared, subsequent event-driven analyses are planned. Confidence in the norovirus study's design, using three different strains for broader coverage, is highlighted, aiming for a readout this year after enrollment completion.

The dialogue discusses a norovirus vaccine study with a trivalent composition targeting strain-matched efficacy, focusing on seropositive adults over 65 for a booster trial. The approach contrasts with previous pediatric trials, aiming to address the disease burden in older adults. The FDA's regulatory path for this placebo-controlled study is anticipated to be clearer, given the lack of comparators, unlike flu vaccine trials where the comparator was a point of discussion.

A question about the status of overall survival (OS) data in a melanoma treatment study was addressed, with the response indicating that the OS curves will be shared at an upcoming medical meeting alongside relapse-free survival data, without revealing further specifics prior to the presentation.

The dialogue covers the demographic breakdown of a flu vaccine efficacy study, emphasizing strong results in older age groups. It also discusses the collaborative regulatory engagement for an individualized neoantigen therapy, noting Merck's role as the sponsor for the Phase 3 study.

A discussion on the potential of a Phase 2 study for renal cell carcinoma (RCC) to serve as a registrational trial, emphasizing the need for a significant benefit. The conversation also explores the appropriateness of using Keytruda or its combinations as comparators in future Phase 3 trials, pending further data. The focus is on confirming int's efficacy across various cancers and the decision-making process with Merck based on emerging data.

The dialogue centered around the potential use of Int in adjuvant melanoma treatment, considering its applicability with various PD-1/PD-L1 inhibitors, including pembrolizumab. It highlighted the interest in broadening the label for Int to include other approved PD-1/PD-L1 treatments in the same indication, emphasizing the goal of maximizing patient access. The conversation also touched upon the impact of subcutaneous versus IV administration of PD-1 antibodies on regimen selection and logistics, asserting that Int's benefits are expected to remain consistent across different administration methods.